Advanced Regenerative Wound Care

Bringing the world's most advanced healing technologies to the patients who need them.

ITG distributes advanced wound care portfolios — antimicrobial matrices, bioengineered tissue allografts, amniotic membrane products, and cold plasma therapy — across Asia, Latin America, and Europe. Regulatory rigor, clinical support, and supply reliability built for markets that demand the highest standard of care.

30+ Years of international
healthcare experience
99.99% Microbial reduction on matrix
Microlyte® · BioLab Holdings
Trusted Manufacturing &
Distribution Partners
sweetbio terraplasma medical
What we do

We don't just move products. We move outcomes.

By bridging cutting-edge U.S. manufacturers with forward-thinking healthcare providers abroad, we enable faster healing, improved patient care, and expanded access to regenerative solutions. Whether you're a clinic in Buenos Aires or a hospital in Bangkok — we deliver the technology, evidence, and support to treat wounds with confidence and precision.

Path 01

For Healthcare Providers

Direct access to U.S.-manufactured amniotic membrane allografts — with the regulatory documentation, clinical support, and reliable supply your patients deserve. Built for hospitals, clinics, and surgeons treating chronic and complex wounds.

  • Full Biolab portfolio — antimicrobial, allograft, bioengineered
  • Shelf-stable products, no cold chain required
  • Country-specific regulatory support
  • Clinical training & case study library
Request Information
Path 02

For Sub-Distributors

Build a region-leading regenerative wound care portfolio with vetted, clinically-validated U.S. biologics. ITG offers prime distribution agreements with regulatory support, marketing tools, and clinical evidence behind every territory.

  • Prime distribution agreements by territory
  • Schedule 3B exclusivity available
  • Co-developed regulatory pathways
  • Marketing collateral & KOL programs
Inquire about Territory
Technologies

A full wound care portfolio. Clinically validated at every level.

ITG's primary portfolio is the Biolab range — antimicrobial matrices, bioengineered tissue allografts, amniotic membrane products, and cold plasma therapy. Multiple modalities. One distribution partner. Backed by peer-reviewed evidence and full clinical documentation in English and Thai.

01
Synthetic Antimicrobial Matrix · BioLab Holdings

Microlyte®

Ionic and metallic silver at low, non-toxic levels — 99.99% microbial reduction on matrix. Conforms to wound-bed micro-crevices, maintains a moist healing environment. 7 sizes. HCPCS A2005.

DFU · VLU Chronic Wounds Antimicrobial
Learn more
02
Bioengineered Wound Product · sweetbio

APIS®

Collagen Derivative + Mānuka Honey + Hydroxyapatite — 2× faster wound closure in published peer-reviewed studies. 4–8 week wound closure, 99.99% bacteria reduction in 24 hours. HCPCS A2010.

Bioengineered Antibacterial DFU · VLU
Learn more
03
Amniotic Membrane Allografts · BioLab Holdings

Membrane Wrap Family

Four amniotic tissue allograft configurations — single, dual, hydrated, and triple-layer amnion-chorion-amnion. All sizes 1×1 through 10×10 cm. 5-year shelf life. FDA compliant.

Amniotic Multi-Layer Surgical
Learn more
Clinical Evidence

The case is closed: advanced regenerative grafts heal what standard care cannot.

Across published clinical studies and real-world outcomes data, the technologies we distribute consistently outperform conventional wound therapy — particularly in chronic ulcers where conventional care fails.

99.99%
Microbial reduction on matrix · Microlyte® · BioLab Holdings
2×
Faster wound closure in published peer-reviewed studies · APIS® by sweetbio
86–90%
Healing rates documented across chronic non-healing wounds with amniotic allografts
1 leg every 30s
Lost globally to diabetic foot ulcer. Advanced regenerative wound care changes that math.
Global Reach

Active across three continents.

From Santiago to Sydney, Buenos Aires to Bangkok, Tokyo to Warsaw — ITG operates a vetted distribution network across markets where advanced regenerative wound care is most needed and most underserved.

Chile Argentina Italy · CH Poland Japan · Korea Taiwan Malaysia AU · NZ

Latin America

  • Chile
  • Argentina

Europe

  • Italy · Switzerland
  • Poland · Finland
  • Bosnia · Croatia
  • Slovenia · Herzegovina
  • Additional EU

Asia-Pacific

  • Japan
  • South Korea
  • Taiwan
  • Malaysia
  • Australia
  • New Zealand
Begin a conversation

Whether you prescribe or distribute — we move outcomes.

From clinicians evaluating the Biolab range for chronic wound cases to in-country distributors building a full regenerative wound care portfolio, ITG is built for the partnerships that change patient lives.

Get in Touch